Aisling Capital

CalciMedica is a biopharmaceutical company focused on developing therapeutics for inflammatory and autoimmune disorders. It specializes in discovering and developing small molecule drugs that target calcium release-activated calcium channels.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Elevation Oncology develops precision medicines for genomically defined cancers. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions, currently in Phase 2 trials.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

Atreca is a biopharmaceutical company that discovers and develops antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from its proprietary discovery platform.

Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the development of therapies for diseases associated with transthyretin (TTR) amyloidosis (ATTR). Founded in 2013, the company is advancing its lead candidate, AG10, which is currently undergoing phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize tetrameric TTR, aiming to interrupt the pathological processes that lead to ATTR. As a subsidiary of BridgeBio Pharma, Eidos Therapeutics is committed to addressing the clinical needs related to TTR and amyloidosis through innovative, genetically targeted therapies.

Zosano Pharma is a clinical-stage biopharmaceutical company developing therapeutics with a proprietary transdermal microneedle delivery system that enables rapid systemic administration of drugs. It focuses on migraine treatments, with its lead candidate Qtrypta (M207), a zolmitriptan formulation designed for quick relief. Founded in 2006 and headquartered in Fremont, California, Zosano aims to improve how migraine therapies are delivered by combining innovative drug delivery technology with clinically meaningful products.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

GTx, Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specialized in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders. Its notable product candidate, enobosarm (GTx-024), was in Phase II clinical trials aimed at treating various forms of breast cancer and offering solutions for postmenopausal women with stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aimed to improve patient outcomes through its targeted therapeutic approaches. In 2019, GTx was acquired by Oncternal Therapeutics, marking the completion of a reverse merger transaction.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative therapies for patients in hospital settings. Founded in 2013, Zavante is focused on creating treatments that address serious and life-threatening infections, particularly those caused by multi-drug resistant bacteria. One of its key pipeline products is ZOLYD, an investigational injectable antibiotic designed to combat these challenging infections. The company's commitment to improving patient outcomes highlights its role in addressing critical healthcare needs within the hospital environment.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Cynapsus is a pharmaceutical company based in Toronto, Ontario, established in 2004, that focuses on developing innovative treatments for Parkinson's disease. The company specializes in creating a non-injectable sublingual thin film formulation, APL-130277, designed for the on-demand management of OFF episodes, which are debilitating periods when symptoms of Parkinson's worsen. Cynapsus has successfully completed a Phase two clinical trial for this product candidate, which utilizes apomorphine hydrochloride as its active ingredient. The company's work aims to enhance the quality of life for individuals living with Parkinson's disease by providing an alternative to traditional injectable therapies.

Aimmune Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for peanut and other food allergies. The company’s primary product candidate, PALFORZIA, utilizes a therapeutic approach known as Characterized Oral Desensitization Immunotherapy (CODIT) to desensitize patients to food allergens. Aimmune is also engaged in research and development of additional CODIT candidates, including AR201, which is in Phase II clinical trials for treating egg allergy in pediatric and young adult populations, as well as other candidates targeting allergies like cow's milk. The company collaborates strategically with Nestlé Health Science to advance food allergy therapeutics and has clinical agreements with Regeneron and Sanofi to study PALFORZIA in conjunction with dupilumab for peanut-allergic patients. Founded in 2011 and headquartered in Brisbane, California, Aimmune Therapeutics was previously known as Allergen Research Corporation before rebranding in 2015 and is now a subsidiary of Société des Produits Nestlé S.A.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Versartis is a biotechnology company focused on developing therapeutic proteins for the treatment of endocrine disorders. Headquartered in Redwood City, California, the company utilizes its proprietary half-life extension technology, XTEN, to create innovative drug candidates aimed at improving patient outcomes. Versartis is currently advancing its lead program, VRS-317, which has recently completed enrollment in a Phase 1 study for adult patients with growth hormone deficiency. Founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures, the company is staffed by experts in drug development and collaborates with external contract services to efficiently implement its product development strategies. Versartis aims to enhance treatment compliance and reduce the burden of daily injections for patients with endocrine disorders, while also targeting critical survival pathways in various malignancies.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Pharmaron offers comprehensive research, development, and manufacturing services across drug discovery, preclinical, and clinical phases for small molecules, biologics, and cell & gene therapies.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

Bridge Pharmaceuticals is a drug development research organization based in Gaithersburg, Maryland. It provides toxicology and pharmacology services to support investigational new drug applications on a global scale.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

CardioKine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company focuses on developing innovative pharmaceuticals aimed at the prevention and treatment of cardiovascular diseases. One of its notable products is lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. CardioKine is dedicated to addressing unmet medical needs in cardiovascular health through its targeted therapeutic compounds.

Advion is a global company founded in 1993 and headquartered in New York, specializing in systems and consumables for life science research. It provides a range of biochemistry analysis equipment, including microfluidic devices and mass spectrometry products aimed at supporting various sectors such as biopharmaceuticals, academic and government research, and industrial chemistry. Advion’s offerings include purpose-built mass spectrometers, nanoelectrospray ionization sources, and flow-chemistry synthesis systems, catering to the needs of pharmaceutical companies, research agencies, and universities worldwide.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. Founded in 1992 and headquartered in Westminster, Colorado, the company is known for its primary product, FOLOTYN, which is a folate analogue metabolic inhibitor designed to preferentially accumulate in cancer cells and induce cell death. As of September 2012, Allos Therapeutics operates as a subsidiary of Spectrum Pharmaceuticals, Inc. The company's mission is to provide innovative small molecule therapeutics for the treatment of cancer.